{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:48Z","timestamp":1792510128658,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020917","name":"Mohammed Bin Rashid University of Medicine and Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103075","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T15:22:53Z","timestamp":1767280973000},"page":"103075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review"],"prefix":"10.1016","volume":"143","author":[{"given":"Noora","family":"Jatan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Talo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida J.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F.","family":"Kellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103075_b0005","unstructured":"Peters A, Tadi P. Aromatase Inhibitors. StatPearls. Treasure Island (FL); 2025."},{"key":"10.1016\/j.ctrv.2025.103075_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1249160","article-title":"Aromatase inhibitors: the journey from the state of the art to clinical open questions","volume":"13","author":"Generali","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103075_b0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2015-0349","article-title":"Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer","volume":"21","author":"Kadakia","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5152\/eurasianjmed.2015.008","article-title":"CYP19A1 Genetic polymorphisms rs4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy","volume":"48","author":"Mazzuca","year":"2016","journal-title":"Eurasian J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2025.103075_b0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.expneurol.2016.04.006","article-title":"Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons","volume":"281","author":"Robarge","year":"2016","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10549-013-2638-3","article-title":"Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study","volume":"140","author":"Garcia-Giralt","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-014-2873-2","article-title":"Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial","volume":"144","author":"Fontein","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.32098\/mltj.03.2014.11","article-title":"Impact of oestrogen deficiency and aging on tendon: concise review","volume":"4","author":"Frizziero","year":"2014","journal-title":"Mus Ligam Tend J"},{"issue":"84","key":"10.1016\/j.ctrv.2025.103075_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15557\/JoU.2021.0001","article-title":"Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: a pilot study","volume":"21","author":"Martinez","year":"2021","journal-title":"J Ultrason"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103075_b0055","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.57.1547","article-title":"Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors","volume":"33","author":"Irwin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jama.2018.8907","article-title":"Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial","volume":"320","author":"Hershman","year":"2018","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103075_b0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202","volume":"36","author":"Henry","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103075_b0070","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103075_b0075","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103075_b0080","unstructured":"Programme CAS. CASP Checklist for Case-Control Studies: CASP; 2024 [Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/case-control-study-checklist\/]."},{"key":"10.1016\/j.ctrv.2025.103075_b0085","unstructured":"Programme CAS. CASP Checklist for Cohort Studies: CASP; 2024 [Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/cohort-study-checklist\/]."},{"key":"10.1016\/j.ctrv.2025.103075_b0090","unstructured":"Programme CAS. CASP Checklist for Cross-Sectional Studies: CASP; 2024 [Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/cross-sectional-studies-checklist\/]."},{"issue":"7454","key":"10.1016\/j.ctrv.2025.103075_b0095","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103075_b0100","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103075_b0105","article-title":"Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10549-013-2504-3","article-title":"Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer","volume":"138","author":"Henry","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103075_b0115","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1078-0432.CCR-23-2137","article-title":"A cohort study to evaluate genetic predictors of aromatase inhibitor musculoskeletal symptoms: results from ECOG-ACRIN E1Z11","volume":"30","author":"Stearns","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103075_b0120","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8842110","article-title":"Musculoskeletal pain during the menopausal transition: a systematic review and meta-analysis","volume":"2020","author":"Lu","year":"2020","journal-title":"Neural Plast"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jpain.2013.11.004","article-title":"Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study","volume":"15","author":"Laroche","year":"2014","journal-title":"J Pain"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103075_b0130","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/ph15121578","article-title":"Aromatase-inhibitor-induced musculoskeletal inflammation is observed independent of oophorectomy in a novel mouse model","volume":"15","author":"Young","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-011-1611-2","article-title":"Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy","volume":"130","author":"Gallicchio","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10549-015-3378-3","article-title":"CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1\u201398 trial","volume":"151","author":"Leyland-Jones","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-020-05777-1","article-title":"Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients","volume":"183","author":"Borrie","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0150","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr2813","article-title":"Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors","volume":"13","author":"Mao","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103075_b0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.breast.2019.10.008","article-title":"Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors","volume":"49","author":"Romero","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4910-z","article-title":"Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer","volume":"172","author":"Borrie","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"10.1016\/j.ctrv.2025.103075_b0165","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1200\/JCO.2010.28.5064","article-title":"Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors","volume":"28","author":"Ingle","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0170","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/bcr3137","article-title":"Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103075_b0175","first-page":"8059","article-title":"Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms","volume":"30","author":"Hertz","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247989","article-title":"Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer","volume":"16","author":"Umamaheswaran","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103075_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133964","article-title":"RANKL and OPG polymorphisms are associated with aromatase inhibitor-related musculoskeletal adverse events in chinese han breast cancer patients","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3816\/CBC.2009.n.006","article-title":"Aromatase Inhibitor\u2013related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?","volume":"9","author":"Muslimani","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103075_b0195","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jbmr.1641","article-title":"Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer","volume":"27","author":"Gallicchio","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103075_b0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3747\/co.v18i6.909","article-title":"A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy","volume":"18","author":"Robidoux","year":"2011","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0205","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1152\/physiolgenomics.00085.2017","article-title":"Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer","volume":"50","author":"Dempsey","year":"2018","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.ctrv.2025.103075_b0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.013","article-title":"Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients","volume":"56","author":"Lintermans","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103075_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.662734","article-title":"Further evidence that OPG rs2073618 is associated with increased risk of musculoskeletal symptoms in patients receiving aromatase inhibitors for early breast cancer","volume":"12","author":"Hertz","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-018-4811-1","article-title":"A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial","volume":"171","author":"Santa-Maria","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0225","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clbc.2017.10.009","article-title":"Vitamin D levels, Vitamin D receptor polymorphisms, and inflammatory cytokines in aromatase inhibitor-induced arthralgias: an analysis of CCTG MA.27","volume":"18","author":"Niravath","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0230","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10549-010-1075-9","article-title":"Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study","volume":"125","author":"Prieto-Alhambra","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/tbj.12227","article-title":"Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms","volume":"20","author":"Singer","year":"2014","journal-title":"Breast J"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-011-1911-6","article-title":"Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole","volume":"132","author":"Singh","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0245","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.NCC.0000339262.44560.92","article-title":"Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy","volume":"32","author":"Waltman","year":"2009","journal-title":"Cancer Nurs"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0250","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-016-3710-6","article-title":"Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)","volume":"155","author":"Shapiro","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-019-05319-4","article-title":"Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia","volume":"177","author":"Niravath","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"30","key":"10.1016\/j.ctrv.2025.103075_b0260","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1200\/JCO.2008.20.5435","article-title":"Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor\u2013related arthralgia","volume":"27","author":"Dizdar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0265","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/annonc\/mds290","article-title":"Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data","volume":"24","author":"Lintermans","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103075_b0270","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdq699","article-title":"Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis","volume":"22","author":"Lintermans","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0275","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000491874","article-title":"Aromatase inhibitor-associated tendinopathy and muscle tendon rupture: report of three cases of this exceedingly rare adverse event","volume":"11","author":"Mitsimponas","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9394-6","article-title":"Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging","volume":"104","author":"Morales","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"10.1016\/j.ctrv.2025.103075_b0285","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/JCO.2007.15.4005","article-title":"Prospective study to assess short-term intra-articular and Tenosynovial changes in the aromatase inhibitor\u2013associated arthralgia syndrome","volume":"26","author":"Morales","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0290","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjc.6605768","article-title":"Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case\u2013control study","volume":"103","author":"Henry","year":"2010","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103075_b0295","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jcm11041067","article-title":"Feasibility trial to evaluate tendon stiffness obtained from shear wave Elastography imaging as a biomarker of aromatase inhibitor-induced Arthralgias","volume":"11","author":"Martinez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2025.103075_b0300","article-title":"Current and future advances in practice: aromatase inhibitor-induced arthralgia","volume":"8(2):rkae024","author":"Kim","year":"2024","journal-title":"Rheumatol adv pract"},{"key":"10.1016\/j.ctrv.2025.103075_b0305","article-title":"Oxylipins as biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in breast cancer patients","volume":"13(3):452","author":"Martinez","year":"2023","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103075_b0310","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.exger.2009.03.003","article-title":"Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis","volume":"44","author":"Jingxuan","year":"2009","journal-title":"Exp Gerontol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0315","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cancers14010206","article-title":"Natural and synthetic Estrogens in chronic inflammation and breast cancer","volume":"14","author":"Maharjan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103075_b0320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13058-015-0599-7","article-title":"Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?","volume":"17","author":"Bauml","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103075_b0325","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10549-011-1849-8","article-title":"The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms","volume":"131","author":"Shanmugam","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103075_b0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11926-009-0052-y","article-title":"The role of interleukin-17 in the pathogenesis of rheumatoid arthritis","volume":"11","author":"Gaffen","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103075_b0335","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/AJP.0000000000001073","article-title":"Increased clinical pain locations and pain sensitivity in women after breast cancer surgery: influence of aromatase inhibitor therapy","volume":"38","author":"Zhu","year":"2022","journal-title":"Clin J Pain"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103075_b0340","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jpain.2014.01.487","article-title":"Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer","volume":"15","author":"Henry","year":"2014","journal-title":"J Pain"},{"key":"10.1016\/j.ctrv.2025.103075_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115600","article-title":"A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders","volume":"425","author":"Collin","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"issue":"23","key":"10.1016\/j.ctrv.2025.103075_b0350","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/0008-5472.CAN-16-1492","article-title":"TRPA1 mediates aromatase inhibitor\u2013evoked pain by the aromatase substrate androstenedione","volume":"76","author":"De Logu","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103075_b0355","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/pharmaceutics15041136","article-title":"Kinin B2 and B1 receptors activation sensitize the TRPA1 channel contributing to anastrozole-induced pain symptoms","volume":"15","author":"Fialho","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103075_b0360","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s12035-023-03654-8","article-title":"TRPV4 Activation and its intracellular modulation mediated by Kinin receptors contribute to painful symptoms induced by Anastrozole","volume":"61","author":"Fialho","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103075_b0365","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00432-013-1391-7","article-title":"Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer","volume":"139","author":"Gallicchio","year":"2013","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:56:36Z","timestamp":1770479796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":73,"alternative-id":["S0305737225001975"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103075","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103075"}}